Images List Premium Download Classic

Diabetes

Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline
Glaxosmithkline Intellectual Property Development Limited
April 12, 2018 - N°20180099955

The present invention relates to the compound (2r,2′r)-bis(((((tetrahydro-2h-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid p component (sap) would be beneficial, including amyloidosis, alzheimer's disease, type 2 diabetes mellitus and osteoarthritis.
Diabetes treatment
Beth Israel Deaconess Medical Center
April 12, 2018 - N°20180099031

Methods and compositions for treating a patient who has recently developed diabetes are provided. The methods can include administering a tolerance-restoring agent to the patient and simultaneously administering intensive insulin therapy.
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Acylated glucagon analogue
Boehringer Ingelheim International Gmbh
April 05, 2018 - N°20180094038

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glp-1 receptor as compared to human glucagon.
Dipeptidyl peptidase-iv (dppiv), inhibitory peptide compound, composition containing the same, and production method for the ...
Maruha Nichiro Corporation
April 05, 2018 - N°20180094027

A peptide compound having a dipeptidyl peptidase-iv (dppiv) inhibitory activity or a composition containing the peptide compound that can make a contribution to the prevention of the onset of pathology or the progression in diabetes mellitus patients or those at risk of diabetes mellitus can be provided according to the present invention by a simple method using, as a raw ...
2-acylaminopropoanol-type glucosylceramide synthase inhibitors
April 05, 2018 - N°20180093981

Or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (i) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment type 2 diabetes mellitus patients
Sanofi-aventis Deutschland Gmbh
April 05, 2018 - N°20180092965

A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
Use of human small leucine zipper protein in adipocyte differentiation procedure
Korea University Research And Business Foundation
April 05, 2018 - N°20180092962

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, slzip binds with pparγ2 to induce the formation of a complex of hdac3 and pparγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of pparγ2 and suppress the differentiation to ...
Compositions containing tannic acids and uses thereof
Syneurx International (taiwan) Corp.
April 05, 2018 - N°20180092935

Compositions (e. G., pharmaceutical compositions, nutraceutical compositions or medical food compositions) comprising tannic acids, particularly tannic acids which are d-amino acid oxidase inhibitor with superior potency, purity and safety profile; and uses thereof for treating cns disorder and obesity disorders including diabetes, hyperglycemia, hyperlipidemia or hypercholesterolemia.
Novel methods of use of tetrahydroberberine (thb)
Dignity Health
April 05, 2018 - N°20180092904

Tetrahydroberberine (thb), isolated from the chinese herb “corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (thb), thb analogs or derivatives, tetrahydroprotoberberines (thpb). Tetrahydroberberine (thb) and analogs such as l-stepholidine (l-spd) potently block functional katp channels natively expressed on midbrain ...
Treating or preventing nephrogenic diabetes insipidus
Emory University
April 05, 2018 - N°20180092876

In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a ampk activator to a subject in need thereof, wherein in certain embodiments, the ampk activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
Capsules with intracapsular microspheres for improved survival and function of encapsulated cells
The Board Of Trustees Of The University Of Illinois
April 05, 2018 - N°20180092855

Provided is a microcapsule for increasing the survival and/or function of a cell, such as an islet cell, microcapsule can include an outer shell comprising a first polymer; an interior core comprising: at least one live cell; a second polymer; and at least one microsphere comprising a third polymer and a compound capable of improving survival of the at ...
Anti-cxcr3 antibodies and methods of use thereof
Genzyme Corporation
March 29, 2018 - N°20180086838

The present disclosure provides anti-cxcr3 antibodies and methods of using the antibodies to diagnose and/or treat cxcr3-associated disorders such as diabetes mellitus type i (t1d), particularly new-onset t1d. In certain embodiments, disclosed herein are cxcr3 neutralizing antibodies.
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of long-acting glp-1 peptides
Novo Nordisk A/s
March 29, 2018 - N°20180085435

The invention relates to use of long-acting glp-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.
Use of tetraspanin-2 for treating diabetes and screening an anti-diabetic agent
Korea Basic Science Institute
March 29, 2018 - N°20180085421

There is provided a method for treating diabetes, the method comprising administering to a subject in need thereof an effective amount of a tetraspanin-2 (tspan2) protein expression or activity inhibitor. Further, there is provided a method for screening a diabetes therapeutic agent, the method comprising: (a) bringing a test material into contact with a cell expressing tspan2 gene; (b) determining ...
Methods for treating ocular diseases
Springsky Biomed Company Limited
March 29, 2018 - N°20180085329

The present invention is related to a method for treating an ocular disease, particularly a diabetes related ocular disease, comprising administering to a subject in need thereof an effective amount of a group of compounds having a structure of formula a1, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (pvr), uveitis, glaucoma and age related ...
Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers
The Florida International University Board Of Trustees
March 22, 2018 - N°20180080944

The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the ...
Method for decreasing the body fat content in a subject by administering an actriib protein
Acceleron Pharma Inc.
March 22, 2018 - N°20180080012

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
Growth differentiation factor 15 (gdf-15) constructs
Amgen Inc.
March 22, 2018 - N°20180079790

Constructs comprising gdf15, and mutants thereof are provided. In various embodiments the constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Treatment of diabetes using agonists of the mas-related gpcr d
March 15, 2018 - N°20180074053

Methods of identifying agonists of mrgd for treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders. Methods of treating prediabetes, type-2 diabetes and cardiovascular diseases or disorders comprising administering to a subject an agonist of mrgd.
Heteroaryl compounds and methods of use thereof
Sunovion Pharmaceuticals Inc.
March 15, 2018 - N°20180072759

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as cns disorders and metabolic disorders, including, but not limited to, e. G., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
Loading